As of 2026-05-22, the EV/EBITDA ratio of Shenzhen Salubris Pharmaceuticals Co Ltd (002294.SZ) is 97.61. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 002294.SZ's latest enterprise value is 56,633.18 mil CNY. 002294.SZ's TTM EBITDA according to its financial statements is 580.19 mil CNY. Dividing these 2 quantities gives us the above 002294.SZ EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 25.9x | 17.8x |
| Forward P/E multiples | 8.4x - 9.8x | 9.0x |
| Fair Price | 5.48 - 10.26 | 8.15 |
| Upside | -84.8% - -71.5% | -77.3% |
| Date | EV/EBITDA |
| 2026-05-20 | 97.61 |
| 2026-05-19 | 98.49 |
| 2026-05-18 | 94.32 |
| 2026-05-15 | 95.66 |
| 2026-05-14 | 98.46 |
| 2026-05-13 | 102.25 |
| 2026-05-12 | 105.41 |
| 2026-05-11 | 117.24 |
| 2026-05-08 | 130.39 |
| 2026-05-07 | 138.22 |
| 2026-05-06 | 137.91 |
| 2026-04-30 | 139.70 |
| 2026-04-29 | 141.37 |
| 2026-04-28 | 144.64 |
| 2026-04-27 | 149.01 |
| 2026-04-24 | 151.31 |
| 2026-04-23 | 152.55 |
| 2026-04-22 | 155.62 |
| 2026-04-21 | 148.87 |
| 2026-04-20 | 153.18 |
| 2026-04-17 | 160.18 |
| 2026-04-16 | 165.10 |
| 2026-04-15 | 183.57 |
| 2026-04-14 | 169.65 |
| 2026-04-13 | 170.17 |
| 2026-04-10 | 171.63 |
| 2026-04-09 | 171.49 |
| 2026-04-08 | 175.36 |
| 2026-04-07 | 177.07 |
| 2026-04-03 | 181.18 |
| 2026-04-02 | 186.40 |
| 2026-04-01 | 180.22 |
| 2026-03-31 | 167.21 |
| 2026-03-30 | 172.12 |
| 2026-03-27 | 168.77 |
| 2026-03-26 | 153.32 |
| 2026-03-25 | 155.51 |
| 2026-03-24 | 152.71 |
| 2026-03-23 | 149.06 |
| 2026-03-20 | 158.40 |
| 2026-03-19 | 157.05 |
| 2026-03-18 | 161.22 |
| 2026-03-17 | 159.71 |
| 2026-03-16 | 150.85 |
| 2026-03-13 | 142.72 |
| 2026-03-12 | 142.80 |
| 2026-03-11 | 146.29 |
| 2026-03-10 | 147.17 |
| 2026-03-09 | 133.69 |
| 2026-03-06 | 138.38 |